½ÃÀ庸°í¼­
»óǰÄÚµå
1424371

¼¼°èÀÇ ÈíÀÔ¾à ½ÃÀå : ¾àÁ¦ Ŭ·¡½ºº°, Á¦Ç° À¯Çüº°, ¿ëµµº°, À¯Åë ä³Îº°, Áö¿ªº°

Global Inhalable Drugs Market, By Drug Class (Inhaled Corticosteroids, Leukotriene modifiers, Long-acting beta agonists, Long-acting muscarinic antagonists, Others), By Product Type, By Application, By Distribution Channel, By Region

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Coherent Market Insights | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ ÈíÀÔ¾à ½ÃÀå ±Ô¸ð´Â 2023³â 348¾ï 6,000¸¸ ´Þ·¯¿¡¼­ 2030³â¿¡´Â 566¾ï 8,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ¿¹Ãø ±â°£ Áß CAGRÀº 7.2%¸¦ ³ªÅ¸³À´Ï´Ù.

¸®Æ÷Æ® ¹üÀ§ ¸®Æ÷Æ® »ó¼¼
±âÁسâ 2022³â 2023/2024³â ½ÃÀå ±Ô¸ð 348¾ï 6,000¸¸ ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ 2018-2021³â ¿¹Ãø ±â°£ 2023-2030³â
¿¹Ãø ±â°£ 2023³â/2024-2030³â/2031³â CAGR 7.20% 2030/2031³â °¡Ä¡ ¿¹Ãø 566¾ï 8,000¸¸ ´Þ·¯
µµÇ¥ 1. ¼¼°èÀÇ ÈíÀÔ¾à ½ÃÀå Á¡À¯À²(%), Áö¿ªº°, 2023³â
Global Inhalable Drugs Market-IMG1

ÈíÀÔ °¡´ÉÇÑ ÀǾàǰÀº Æó¸¦ ÅëÇØ È£Èí±â¸¦ ÅëÇØ ±¹¼ÒÀûÀ¸·Î Åõ¿©ÇÏ¿© ºü¸¥ Ä¡·á È¿°ú¸¦ ³ªÅ¸³»´Â ÀÇ·á¿ë ¹°ÁúÀÔ´Ï´Ù. õ½Ä, ¸¸¼ºÆó¼â¼ºÆóÁúȯ, ³¶Æ÷¼º ¼¶À¯Áõ µî ÆóÁúȯ Ä¡·á¿¡ ƯÈ÷ È¿°úÀûÀÔ´Ï´Ù. Æó´Â ¼ÒÈ­°üÀ» ÅëÇÑ °æ±¸ Åõ¿©¿¡ ºñÇØ ¾à¹° Èí¼ö¸¦ À§ÇÑ °Å´ëÇÑ Ç¥¸éÀûÀ» Á¦°øÇÕ´Ï´Ù. ÈíÀÔ °¡´ÉÇÑ ¾à¹°Àº °£ 1Â÷ Åë°ú ´ë»ç¸¦ ¿ìȸÇÏ¿© Æó Á¶Á÷¿¡ Á÷Á¢ ¾à¹°À» ½Å¼ÓÇÏ°Ô Àü´ÞÇÏ¿© Àü½Å ¼öÁØÀ» ³·Ãâ ¼ö ÀÖ½À´Ï´Ù. ÁÖ¿ä ÀåÁ¡Àº °æ±¸¿ë ¾à¹°¿¡ ºñÇØ ¸î ºÐ À̳»¿¡ ºü¸¥ ¾àÈ¿ ¹ßÇö, Àú¿ë·® Åõ¿©, ºÎÀÛ¿ë °¨¼Ò µîÀ» µé ¼ö ÀÖ½À´Ï´Ù. Àαâ ÀÖ´Â ÈíÀÔÁ¦¿¡´Â ¾ËºÎÅ׷Ѱú °°Àº õ½Ä ¹× ¸¸¼ºÆó¼â¼ºÆóÁúȯ¿ë ±â°üÁöÈ®ÀåÁ¦, ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵å, ºÐ »ê¼º Ç×»ýÁ¦, Àν¶¸° µîÀÌ ÀÖ½À´Ï´Ù. Àü ¼¼°è¿¡¼­ ÆóÁúȯÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ÈíÀÔÇü ÀǾàǰ ½ÃÀåÀº ¾ÕÀ¸·Îµµ ¾ÈÁ¤ÀûÀÎ ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù.

½ÃÀå ¿ªÇÐ:.

¼¼°è ÈíÀÔÁ¦ ½ÃÀåÀº õ½Ä ¹× COPD¿Í °°Àº È£Èí±â ÁúȯÀÇ Àü ¼¼°è À¯º´·ü Áõ°¡¿¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î 2023³â 3¿ù 16ÀÏ ¼¼°èº¸°Ç±â±¸(WHO)¿¡ µû¸£¸é ¸¸¼ºÆó¼â¼ºÆóÁúȯ(COPD)Àº ¼¼°è 3À§ÀÇ »ç¸Á¿øÀÎÀ̸ç, 2021³â¿¡´Â 3¾ï ¸í ÀÌ»óÀÌ Ãµ½ÄÀ¸·Î °íÅë¹Þ°í, ¸Å³â 300¸¸ ¸í ÀÌ»óÀÌ COPD·Î »ç¸ÁÇÒ °ÍÀ¸·Î ¿¹»óÇß½À´Ï´Ù. ¿À¿° ¼öÁØ Áõ°¡¿Í »ýȰ½À°üÀÇ º¯È­´Â Æó ÁúȯÀÇ ¹ßº´·ü Áõ°¡¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÀÌ ½ÃÀåÀº ¶ÇÇÑ È£Èí±â¿¡ Á÷Á¢ÀûÀ¸·Î ¿µÇâÀ» ¹ÌÄ¡´Â ÁúȯÀ» Ä¡·áÇÏ´Â µ¥ ÀÖÀ¸¸ç, ÈíÀÔ °¡´ÉÇÑ ¾à¹°ÀÇ ¿ì¼öÇÑ Ä¡·á È¿°úÀÇ ÇýÅÃÀ» ´©¸®°í ÀÖ½À´Ï´Ù. Á¤·®Àû ÈíÀÔ±â(MDI)¿Í °ÇÁ¶ ºÐ¸» ÈíÀÔ±â(DPI)¿Í °°Àº ¾à¹°Àü´Þ ÀåºñÀÇ ±â¼ú ¹ßÀüÀº »õ·Î¿î Ä¡·á ±âȸ¸¦ È®´ëÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª ÈíÀÔ °¡´ÉÇÑ ¾à¹°ÀÇ °³¹ß ¹× »ý»ê°ú °ü·ÃµÈ ³ôÀº ºñ¿ëÀº ´õ ³ÐÀº ½ÃÀåÀÇ ¼ºÀåÀ» Á¦ÇÑÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ Æó ¾à¹°Àü´Þ ½Ã½ºÅÛÀÇ ÀÓ»ó½ÃÇè ¹× Á¦Ç° ½ÂÀο¡ ´ëÇÑ ¾ö°ÝÇÑ ±ÔÁ¦ ¿ª½Ã Á¦¾à ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ±×·³¿¡µµ ºÒ±¸Çϰí ÷´Ü Á¦Çü ¹× º´¿ë ¿ä¹ý¿¡ ´ëÇÑ ¿¬±¸°³¹ßÀÌ ÁøÇà ÁßÀ̱⠶§¹®¿¡ ¿¹Ãø ±â°£ Áß »õ·Î¿î ±æÀÌ ¿­¸± ¼ö ÀÖ½À´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

  • ¼¼°èÀÇ ÈíÀÔ °¡´É ¾àÁ¦ ½ÃÀåÀ» »ó¼¼ ºÐ¼®Çϰí 2022³âÀ» ±âÁسâÀ¸·Î ÇÑ ¿¹Ãø ±â°£(2023-2030³â)ÀÇ ½ÃÀå ±Ô¸ð¿Í ¿¬Æò±Õ ¼ºÀå·ü(CAGR %)À» Á¦°øÇÕ´Ï´Ù.
  • ¶ÇÇÑ ´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀû ¸ÅÃâ ±âȸ¸¦ ¼³¸íÇϰí, ÀÌ ½ÃÀå¿¡ ´ëÇÑ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¿¡ ´ëÇØ ¼³¸íÇϰí ÀÖ½À´Ï´Ù.
  • ¶Ç ½ÃÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç° Ãâ½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÌ Ã¤ÅÃÇÏ´Â °æÀï Àü·« µî¿¡ °üÇÑ ÁÖ¿ä ÀλçÀÌÆ®µµ Á¦°øÇϰí ÀÖ½À´Ï´Ù.
  • ±â¾÷ ÇÏÀ̶óÀÌÆ®, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä ÇÏÀ̶óÀÌÆ®, À繫 ½ÇÀû, Àü·« µîÀÇ ÆÄ¶ó¹ÌÅÍ¿¡ ±â¹ÝÇÏ¿© ¼¼°èÀÇ ÈíÀÔ °¡´É ¾àÁ¦ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷À» ÇÁ·ÎÆÄÀϸµÇϰí ÀÖ½À´Ï´Ù.
  • ÀÌ ¸®Æ÷Æ®·ÎºÎÅÍ ÀλçÀÌÆ®´Â ¸¶ÄÉÆÃ ´ã´çÀÚ ¹× ±â¾÷ÀÇ °æ¿µÁøÀÌ ÇâÈÄ Á¦Ç°ÀÇ ¹ß¸Å, À¯Çü ¾÷±×·¹À̵å, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü¼ú¿¡ °üÇÑ Á¤º¸¿¡ ±â¹ÝÇÑ ÀÇ»ç°áÁ¤À» ½ÃÇàÇÏ´Â °ÍÀ» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù.
  • ¼¼°èÀÇ ÈíÀÔ¾à ½ÃÀå ¸®Æ÷Æ®´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô Âü¿©¾÷ü, À繫 ¾Ö³Î¸®½ºÆ® µî ÀÌ ¾÷°èÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¿¡°Ô ´ëÀÀÇϰí ÀÖ½À´Ï´Ù.
  • ÀÌÇØ°ü°èÀÚ´Â ¼¼°èÀÇ ÈíÀÔ °¡´ÉÇÑ ¾àÁ¦ ½ÃÀåÀ» ºÐ¼®ÇÒ ¶§ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤À» ¿ëÀÌÇÏ°Ô ÇÒ ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»çÀÇ ¸ñÀû°ú ÀüÁ¦Á¶°Ç

  • Á¶»ç ¸ñÀû
  • ÀüÁ¦Á¶°Ç
  • ¾à¾î

Á¦2Àå ½ÃÀå Àü¸Á

  • ¸®Æ÷Æ® ¼³¸í
    • ½ÃÀåÀÇ Á¤ÀÇ¿Í ¹üÀ§
  • ÁÖ¿ä ¿ä¾à
  • Coherent Opportunity Map(COM)

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

  • ½ÃÀå ¿ªÇÐ
  • ±ÔÁ¦ ½Ã³ª¸®¿À
  • PEST ºÐ¼®
  • PorterÀÇ »ê¾÷ ºÐ¼®
  • ÇÕº´, Àμö, Çù¾÷

Á¦4Àå ¼¼°èÀÇ ÈíÀÔ¾à ½ÃÀå - Äڷγª¹ÙÀÌ·¯½º(COVID-19) ÆÒµ¥¹ÍÀÇ ¿µÇâ

  • ½ÅÁ¾ Äڷγª¹ÙÀÌ·¯½º °¨¿°Áõ(COVID-19)ÀÇ ¿ªÇÐ
  • °ø±ÞÃø°ú ¼ö¿äÃø ºÐ¼®
  • °æÁ¦Àû ¿µÇâ

Á¦5Àå ¼¼°èÀÇ ÈíÀÔ¾à ½ÃÀå, ¾àÁ¦ Ŭ·¡½ºº°, 2018-2030³â

  • ¼­·Ð
  • ÈíÀÔ ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵å
  • ·ùÄÚÆ®¸®¿£ ¼ö½ÄÁ¦
  • Àå½Ã°£ ÀÛ¿ëÇü ¥â±æÇ×Á¦(LABA)
  • Àå½Ã°£ ÀÛ¿ëÇü ¹«½ºÄ«¸° ±æÇ×Á¦(LAMA)
  • ±âŸ

Á¦6Àå ¼¼°èÀÇ ÈíÀÔ¾à ½ÃÀå, Á¦Ç° À¯Çüº°, 2018-2030³â

  • ¼­·Ð
  • ¿¡¾î·ÎÁ¹
  • µå¶óÀÌ ÆÄ¿ì´õ Á¦Á¦
  • ºÐ»ç
  • ±âŸ

Á¦7Àå ¼¼°èÀÇ ÈíÀÔ¾à ½ÃÀå, ¿ëµµº°, 2018-2030³â

  • ¼­·Ð
  • È£Èí±âÁúȯ
  • õ½Ä
  • ¸¸¼ºÆó¼â¼ºÆóÁúȯ(COPD)
  • ³¶Æ÷¼º¼¶À¯Áõ
  • ¾Ë·¹¸£±â¼º ºñ¿°
  • ±âŸ
  • ºñÈ£Èí±âÁúȯ

Á¦8Àå ¼¼°èÀÇ ÈíÀÔ¾à ½ÃÀå, À¯Åë ä³Îº°, 2018-2030³â

  • ¼­·Ð
  • º´¿ø ¾à±¹
  • ¼Ò¸Å ¾à±¹
  • ¿Â¶óÀÎ ¾à±¹

Á¦9Àå ¼¼°èÀÇ ÈíÀÔ¾à ½ÃÀå, Áö¿ªº°, 2018-2030³â

  • ¼­·Ð
  • ºÏ¹Ì
  • ¹Ì±¹
  • ij³ª´Ù
  • À¯·´
  • µ¶ÀÏ
  • ¿µ±¹
  • ½ºÆäÀÎ
  • ÇÁ¶û½º
  • ÀÌÅ»¸®¾Æ
  • ·¯½Ã¾Æ
  • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
  • Áß±¹
  • Àεµ
  • ÀϺ»
  • È£ÁÖ
  • Çѱ¹
  • ASEAN ±¹°¡
  • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
  • ºê¶óÁú
  • ¾Æ¸£ÇîÆ¼³ª
  • ¸ß½ÃÄÚ
  • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿
  • GCC ±¹°¡
  • À̽º¶ó¿¤
  • ±âŸ Áßµ¿
  • ¾ÆÇÁ¸®Ä«
  • ºÏ¾ÆÇÁ¸®Ä«
  • Áß¾Ó¾ÆÇÁ¸®Ä«
  • ³²¾ÆÇÁ¸®Ä«

Á¦10Àå °æÀï ±¸µµ

  • ±â¾÷ °³¿ä
    • GSK plc.
    • Mundipharma International.
    • Boehringer Ingelheim International GmbH.
    • Cipla Inc.
    • AstraZeneca
    • Sanofi
    • Vectura Group Ltd.
    • Viatris Inc.
    • 3M Health Care
    • Allied Healthcare Products, Inc.
    • CareFusion Corporation
    • GF Health Products, Inc.
    • Merck &Co., Inc.
    • Novartis AG
    • Omron Healthcare, Inc.
    • Glenmark Pharmaceuticals
    • PARI Respiratory Equipment, Inc.

Á¦11Àå ¼½¼Ç

  • ÂüÁ¶
  • Á¶»ç ¹æ¹ý
  • ÃâÆÇ»ç ¼Ò°³
KSA 24.02.23

Global inhalable drugs market size is expected to reach US$ 56.68 Bn by 2030, from US$ 34.86 Bn in 2023, exhibiting a CAGR of 7.2% during the forecast period.

Report Coverage Report Details
Base Year: 2022 Market Size in 2023/2024: US$ 34.86 Bn
Historical Data for: 2018 to 2021 Forecast Period: 2023 - 2030
Forecast Period 2023/2024 to 2030/2031 CAGR: 7.20% 2030/2031 Value Projection: US$ 56.68 Bn
Figure 1. Global Inhalable Drugs Market Share (%), By Region, 2023
Global Inhalable Drugs Market - IMG1

Inhalable drugs are medical substances that can be administered locally through the respiratory tract via the lung for rapid therapeutic effects. They are particularly effective for treating lung conditions such as asthma, chronic obstructive pulmonary disease and cystic fibrosis. The lung provides huge surface area for drug absorption as compared to oral administration through the gastrointestinal tract. Inhalable drugs bypass hepatic first-pass metabolism for faster delivery of medications directly to the lung tissues and lower systemic levels. Some key advantages include rapid onset of action within minutes, lower dosing, and reduced side effects as compared to oral medications. Popular inhalable drugs include bronchodilators for asthma and chronic obstructive pulmonary disease like albuterol, corticosteroids, dispersible antibiotics, and insulin. With rising lung diseases globally, the inhalable drugs market is expected to grow steadily in the future.

Market Dynamics:

Global inhalable drugs market is driven by the growing prevalence of respiratory diseases such as asthma and COPD worldwide. For instance, on March 16, 2023, according to the World Health Organization (WHO), chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide, and over 300 Mn people suffered from asthma in 2021, while over 3 Mn people die each year from COPD. Increasing pollution levels and changing lifestyles have contributed to the rising caseload of lung illnesses. The market also benefits from the superior therapeutic efficacy of inhalable drugs in treating conditions, affecting the respiratory tract directly. Technological advancements in drug delivery devices such as metered-dose inhalers (MDIs) and dry powder inhalers (DPIs) are expanding opportunities for novel therapies. However, high costs that are associated with development and production of inhalable drugs limit wider market growth. Additional constraints include stringent regulations around clinical trials and product approval for pulmonary drug delivery systems. Nevertheless, ongoing research and development (R&D) into advanced formulations and combination therapies could unlock new avenues over the forecast period.

Key features of the study:

  • This report provides in-depth analysis of the global inhalable drugs market, and provides market size (US$ Bn) and compound annual growth rate (CAGR %) for the forecast period (2023-2030), considering 2022 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global inhalable drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include GSK plc, Mundipharma International., Boehringer Ingelheim International GmbH., Cipla Inc., AstraZeneca, Sanofi, Vectura Group Ltd, Viatris Inc, 3M Health Care, Allied Healthcare Products, Inc., CareFusion Corporation, GF Health Products, Inc., Merck & Co., Inc., Novartis AG, Omron Healthcare, Inc., Glenmark Pharmaceuticals and PARI Respiratory Equipment, Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • Global inhalable drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global inhalable drugs market

Detailed Segmentation:

  • Global Inhalable Drugs Market, By Drug Class
    • Inhaled Corticosteroids
    • Leukotriene modifiers
    • Long-acting beta agonists (LABAs)
    • Long-acting muscarinic antagonists (LAMAs)
    • Others
  • Global Inhalable Drugs Market, By Product Type
    • Aerosol
    • Dry powder Formulation
    • Spray
    • Others
  • Global Inhalable Drugs Market, By Application
    • Respiratory Diseases
    • Asthma
    • Chronic Obstructive Pulmonary Disease (COPD)
    • Cystic Fibrosis
    • Allergic Rhinitis
    • Others
    • Non-respiratory Disease
  • Global Inhalable Drugs Market, By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Inhalable Drugs Market, By Region
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East & Africa
  • Top Companies in the Global Inhalable Drugs Market:
    • GSK plc.
    • Mundipharma International.
    • Boehringer Ingelheim International GmbH.
    • Cipla Inc.
    • AstraZeneca
    • Sanofi
    • Vectura Group Ltd.
    • Viatris Inc.
    • 3M Health Care
    • Allied Healthcare Products, Inc.
    • CareFusion Corporation
    • GF Health Products, Inc.
    • Merck & Co., Inc.
    • Novartis AG
    • Omron Healthcare, Inc.
    • Glenmark Pharmaceuticals
    • PARI Respiratory Equipment, Inc.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Global Inhalable Drugs Market, By Drug Class
    • Global Inhalable Drugs Market, By Product Type
    • Global Inhalable Drugs Market, By Application
    • Global Inhalable Drugs Market, By Distribution Channel
    • Global Inhalable Drugs Market, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Growing prevalence of respiratory diseases
    • Risk of misuse of inhalable medicines
    • Emergence of new drug delivery technologies
  • Key Highlights
  • Regulatory Scenario
  • Recent Trends
  • PEST Analysis
  • PORTER's Analysis
  • Mergers, Acquisitions, and Collaborations

4. Global Inhalable Drugs Market- Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Global Inhalable Drugs Market, By Drug Class, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019 - 2030
    • Segment Trends
  • Inhaled Corticosteroids
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Leukotriene modifiers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Long-acting beta antagonists (LABAs)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Long-acting muscarinic antagonists (LAMAs)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

6. Global Inhalable Drugs Market, By Product Type, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019 - 2030
    • Segment Trends
  • Aerosol
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Dry powder Formulation
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Spray
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

7. Global Inhalable Drugs Market, By Application, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019 - 2030
    • Segment Trends
  • Respiratory Diseases
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Asthma
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Cystic Fibrosis
  • Allergic Rhinitis
  • Others
  • Non-respiratory Disease
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

8. Global Inhalable Drugs Market, By Distribution Channel, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019 - 2030
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

9. Global Inhalable Drugs Market, By Region, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, By Region, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, For Region, 2019 -2030
    • Country Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
  • U.S.
  • Canada
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2018-2030,(US$ Bn)
  • North Africa
  • Central Africa
  • South Africa

10. Competitive Landscape

  • Company Profile
    • GSK plc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
    • Mundipharma International.
    • Boehringer Ingelheim International GmbH.
    • Cipla Inc.
    • AstraZeneca
    • Sanofi
    • Vectura Group Ltd.
    • Viatris Inc.
    • 3M Health Care
    • Allied Healthcare Products, Inc.
    • CareFusion Corporation
    • GF Health Products, Inc.
    • Merck & Co., Inc.
    • Novartis AG
    • Omron Healthcare, Inc.
    • Glenmark Pharmaceuticals
    • PARI Respiratory Equipment, Inc.
  • Analyst Views

11. Section

  • Reference
  • Research Methodology
  • About us
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦